Neogene Therapeutics

Neogene Therapeutics, Inc. is a global biotechnology company focused on the discovery, development, and manufacturing of next-generation transformative TCR therapies targeting neoantigens in solid cancers. Neogene is advancing fully individualized TCR therapies as well as TCR therapies targeting shared neoantigens, including mutated KRAS (mKRAS) and mutated TP53 (mTP53). Neogene’s novel approach provides a customized therapy based on neoantigen-targeting TCR genes that target neoantigens found in an individual patient's tumor. Our proprietary TCR identification and selection platform enables us to identify neoantigen-specific TCR genes. These TCR genes are engineered into patient-derived T cells using internally developed T-cell engineering technology, with the aim of eliciting strong and durable responses across various solid tumor indications. The ability of these engineered T cells to attack a patient’s tumor can be further modulated by additional targeted genetic modifications that Neogene is exploring for this purpose.